(153 cm i.d.) eluting sequentially with MeOH-H2O 40:60 (2 L) and MeOH (1 L) to afford fractions A and B, respectively. Fraction A (6.1 g) was further separated by a silica gel column (173 cm i.d.) with CHCl 3 -MeOH 95:5 (750 mL) and then CHCl 3 -MeOH 90:10 (900 mL) to give 11 fractions (150 mL each). Fractions 1-5 was combined and evaporated to obtain fraction A1 (1.3 g).
Fraction 6 was evaporated to obtain fraction A2 (0.3 g). Fraction 7 was evaporated to obtain fraction A3 (1.6 g). Fractions 8-11 was combined and evaporated to obtain fraction A4 (2.4 g). Fraction A1 was purified by preparative reverse-phase HPLC with MeOH-H 2 O (45:55) to afford 1 (68 mg); fraction A2 was purified by preparative reverse-phase HPLC with MeOH-H 2 O (45:55) to afford 4 (12 mg); fraction A3 was purified by preparative reverse-phase HPLC with MeOH-H 2 O (45:55) to afford 2 (3 mg) and 3 (4 mg). 3423, 2926, 2874, 1710, 1638, 1542, 1458, 1384, 1268, 1251, 1024 cm Cambridge Soft Corporation). A standard dynamics cascade protocol was used for calculating the three-dimensional structure, in five steps: minimization, minimization2, heating, equilibration and production. The protocol provides the total energy values to standardize validation of any conformations. The conformation generation algorithms are Windows OS compatible; in the current study three-dimensional conformations were generated on an Intel CoreTM i7-920 processor with 3GB RAM and NVIDIA Quadro FX1700 512MB, running Windows XP Pro SP3.
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